30 closest matches · ranked by relevance
Degradation of Top2b and Top2a in Human by Dexrazoxane · Time Course and Degradation of Top2b in Human by Dexrazoxane · Effects of Dexrazoxane on Healthy Human
Primary: Participants With 95% Reduction in Topoisomerase 2 b From Baseline — 0; 0; 0; 0 Participants
Extravasations of Anthracycline Anti-cancer Agents
Primary: Adverse Events — 2 participants
Cancer Other Than Leukemia
Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg
Advanced Solid Tumor
Primary: Period 1: Percent Urinary Recovery (Feurine) of Total Radioactivity — 15.8 percentage of administered dose (%)
Prostate Cancer
Primary: PSA of <_ 0.05 ng/ml After Radical Prostatectomy or Radiation Therapy and PSA <_ 2.0 ng/ml for Patients With Clinical Metastases Without Prior Definitive Therapy — 9…
Lung Cancer, Non-Small Cell · Non-Small-Cell Lung Cancer
Primary: Median Time of Overall Survival — 30.7; 28.6 Weeks — p=0.9460
HTLV-I Infection · T Cell Leukemia
Primary: Duration of Response — 114 Weeks
Carcinoma, Non-Small -Cell Lung · Ovarian Neoplasms · Small Cell Lung Carcinoma
Primary: Ph I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Topotecan — 1.25 mg/m^2
Sarcoma, Soft Tissue · Soft Tissue Sarcoma · Undifferentiated Pleomorphic Sarcoma
Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months
Breast Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 28; 31 percentage of patients
Adult Liposarcoma · Metastatic Liposarcoma · Metastatic Osteosarcoma
Primary: Progression Free Survival at 12 Weeks for Patients With Soft Tissue Sarcoma (STS) Treated With Pazopanib and Oral Topotecan — 57.5 percentage of patients progression free
Small Cell Lung Cancer
Primary: Duration of Severe (Grade 4) Neutropenia in Cycle 1 — 8; 1; 2; 14 days — p=<0.0001
Advanced Breast Cancer
Primary: Number of Patients With a Disease Progression Event — 24; 18 Participants
Metastatic Breast Cancer
Primary: Determination of the Maximum Tolerated Dose (MTD) of Dasatinib When Given in Combination With Ixabepilone (Phase I) — 100 mg daily
Acute Lymphoblastic Leukemia (ALL)
Primary: Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity…
Tumors
Primary: Maximum Tolerated Dose (MTD) of Single Agent Metronomic Oral Topotecan — 1.0 mg/day
Breast Cancer
Primary: Pathologic Complete Response Rate (pCR) — 27 participants
Breast Cancer
Primary: Percentage of Participants With Disease-free Survival (DFS) — 78.97; 83.37 Percentage of participants — p=0.175
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
Advanced Malignant Solid Tumors
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Dextromethorphan and Dextrorphan 3 Days Prior to PF-00299804 Dosing — 206.4; 2199…
Leukemia
Primary: Participants With a Response — 49; 19 Participants
Acute Myeloid Leukemia
Primary: Phase 1 - Dose Finding — 10; 15; 20; 20 mg/m^2
Malignant Melanoma
Primary: Percentage of Participants That Experienced a Dose Limiting Toxicity (DLT) — 0; 17 percentage of participants
Triple-negative Metastatic Breast Cancer
Primary: Objective Response Rate — 26 percentage of participants
Prostate Cancer
Primary: PSA Response Rate — 15.4 percentage of participants
Ovarian Cancer · Peritoneal Neoplasms · Fallopian Tube Cancer
Primary: Dose Limiting Toxicity (DLT) — 2; 3; 4 Dose Limiting Toxicities
Breast Cancer
Primary: Pathological Tumor Response to Neoadjuvant Chemotherapy (Taxotere and AC) — 3; 9; 2; 1 participants
Myelodysplastic Syndrome
Primary: Dosage Determination for IV-infusion of Vosaroxin in Int-2 or High-risk Mds — 200 mg/m^2
Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) — 38.9 percentage of participants
Ovarian Cancer · Primary Peritoneal Cancer · Serous Carcinoma Cancer
Primary: Percentage of Participants With an Overall Response Rate — 9.5; 5.6; 0; 11.8 percentage of participants